CN108333261A - The method for detecting the method for proteic charge variant and determining biological products production technology - Google Patents
The method for detecting the method for proteic charge variant and determining biological products production technology Download PDFInfo
- Publication number
- CN108333261A CN108333261A CN201710042581.9A CN201710042581A CN108333261A CN 108333261 A CN108333261 A CN 108333261A CN 201710042581 A CN201710042581 A CN 201710042581A CN 108333261 A CN108333261 A CN 108333261A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- exchange
- column
- biological products
- elution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
A method of detection proteic charge variant.This method includes being analyzed testing protein by pH IEC ion-exchange chromatographies, to obtain chromatogram；And it is based on the chromatogram, determine the content of the testing protein charge alterations body.Using it is according to the ... of the embodiment of the present invention detection proteic charge variant method can realize to proteic charge variant it is quick, accurate, delicately detect.Method described herein is particularly suitable for the detection of the protein product or proteic charge variant in recombinant monoclonal antibodies product for the recombinant DNA that pI values (isoelectric point) are 5.5~8.0.
Description
Technical field
The present invention relates to biomedicine fields, in particular it relates to detect proteic charge variant method and really
Determine the method for biological products production technology.
Background technology
Currently, people's recombinant DNA protein product or people are thin using mammal mostly with recombinant monoclonal antibodies product
Cellular expression system is produced, durings the production of product, storage, transport etc., often occur product aggregation, degradation and
Various posttranslational modifications, so as to cause the inhomogeneities such as the molecular size of product, charge, glycosylation modified and its corresponding variant
It generates.The formation of these variants is likely to occur in any stage in the whole life cycle of product, has data to show, only translates
Afterwards modification (such as the cyclisation of N- terminal glutamates, the amputation of C- terminal lysines, N- terminal glutamins/glutamic acid cyclisation, deamidation,
Oxidation, sialic acid modification etc.) heterogeneity i.e. up to 2.85 × 108.The changeable monoclonal antibody of these nearly all posttranslational modifications
Surface charge distribution characteristic, and charge heterogeneity plays the stability and its biological function of monoclonal antibody has important influence
And become Key Quality attribute (CQA), and charge heterogeneity can reflect the stability of its production technology, so by biological skill
Art industrial circle and regulatory agency pay close attention to.
The parts Q6B are according to monoclonal antibody variant in the guideline that International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use ICH is put into effect
To Product Safety, the influence degree of validity, product related substances and product related impurities are classified as, to product correlative
Discriminating, quality research and the quality control of matter and product related impurities are of great significance.In process of production, especially in life
After production. art changes, also need further to monitor the Crack cause of charge variants and its influence to Product Safety, validity.It is logical
The modes such as change process conditions, formulation method are crossed to reduce charge variants, and assess the charge variants of antibody, with determination
Whether need as clearance standard and as the reference standard of homogeneity of product.
Invention content
The present invention is directed to solve at least some of the technical problems in related technologies.For this purpose, the present invention
One purpose is to propose a kind of method that can quickly, accurately, delicately detect proteic charge variant.
It should be noted that proteic charge variant described herein refers to modification (such as sialylated) after protein translation
The isomers for causing proteic charge amount to change and being formed.
In addition, it is necessary to explanation, pH-IEC ion-exchange chromatographies (pH Gradient Ion Exchange
Chromatography, pH gradient ion-exchange chromatography) specific separation principle be, pH gradient can change detection substance electricity
Lotus, the degree for deviateing isoelectric point, to influence the binding ability of the molecule with positive/negative charge or ion and chromatographic column fixed phase,
Complexity when elution changes, final to realize each component separation to change the selectivity of separation.
In the first aspect of the present invention, the present invention proposes a kind of method of detection proteic charge variant.According to this hair
Bright embodiment, this method include being analyzed testing protein by pH-IEC ion-exchange chromatographies, to obtain chromatography
Figure；And it is based on the chromatogram, determine the content of the testing protein charge alterations body.Using according to the ... of the embodiment of the present invention
Detection proteic charge variant method can realize to proteic charge variant it is quick, accurate, delicately detect.The application institute
The method stated be particularly suitable for pI values be 5.5~8.0 recombinant DNA protein product or recombinant monoclonal antibodies product in albumen
The detection of charge alterations body.
According to an embodiment of the invention, the method for the detection proteic charge variant can further include following attached
Add at least one technical characteristic：
According to an embodiment of the invention, mobile phase used by the pH-IEC ion-exchange chromatographies be piperazine, imidazoles,
The mixed solution of Tris and water, wherein the mass ratio of the piperazine, imidazoles and Tris is 2:0.4:1.2.Inventor is in an experiment
It was found that using the mass ratio of piperazine, imidazoles and Tris for 2:0.4:1.2 mixed solution is as mobile phase, each variant peak base
This is detached with main peak realization.
According to an embodiment of the invention, a concentration of 2g/L of the piperazine, a concentration of 0.4g/L of the imidazoles, it is described
A concentration of 1.2g/L of Tris.Inventor has found in an experiment, using the concentration of aforementioned piperazine, imidazoles and Tris, variant peak
And peak shape good with main peak separating degree is sharp symmetrical, it can be achieved that accurate quantitative analysis to protein variants.
According to an embodiment of the invention, chromatographic column used by the pH-IEC ion-exchange chromatographies is handed over for strong cation
Change chromatographic column SCX or strong anion exchange chromatographic column SAX.Inventor in an experiment, compared to use weak ion-exchange chromatography,
Such as weakly strictly diagonally dominant matrix column WCX, can effectively be controlled between proteic charge variant peak using SCX or SAX and albumen electricity
Separating degree between He Bianyitifeng and main peak controls appearance time.
According to an embodiment of the invention, chromatographic column used by the pH-IEC ion-exchange chromatographies is handed over for strong cation
Chromatographic column SCX is changed, the pH of mobile phase A is 6.5, and the pH of Mobile phase B is 10.5.Inventor has found in an experiment, in above-mentioned stream
Under the pH of dynamic phase, pH gradient is big, and proteic charge variant peak and main peak retention time are suitable, and separating degree is good.
According to an embodiment of the invention, chromatographic column used by the pH-IEC ion-exchange chromatographies is handed over for strong anion
Chromatographic column SAX is changed, the pH of mobile phase A is 10.5, and the pH of Mobile phase B is 6.5.Inventor has found in an experiment, in above-mentioned stream
Under the pH of dynamic phase, pH gradient is big, and proteic charge variant peak and main peak retention time are suitable, and separating degree is good.
According to an embodiment of the invention, chromatographic column used by the pH-IEC ion-exchange chromatographies is handed over for strong cation
Chromatographic column SCX is changed, the elution time of the pH-IEC ion-exchange chromatographies is 30min, and elution slope is 3.3%.Inventor
Find in an experiment, under above-mentioned elution time and slope, proteic charge variant peak realization be kept completely separate (acidic variant and
The realization of alkaline variant is kept completely separate, variant peak and main peak are kept completely separate), appearance time appropriately and resolving power is more excellent.
According to an embodiment of the invention, chromatographic column used by the pH-IEC ion-exchange chromatographies is handed over for strong anion
Chromatographic column SAX is changed, the elution time of the pH-IEC ion-exchange chromatographies is 40min, and elution slope is 2.5%.Inventor
Find in an experiment, under above-mentioned elution time and slope, proteic charge variant peak realization be kept completely separate (acidic variant and
The realization of alkaline variant is kept completely separate, variant peak and main peak are kept completely separate), appearance time appropriately and resolving power is more excellent.
According to an embodiment of the invention, chromatographic column used by the pH-IEC ion-exchange chromatographies is handed over for strong cation
Change chromatographic column SCX, the volume ratio of mobile phase A and Mobile phase B used by the pH-IEC ion-exchange chromatographies is 1:1, and
And used elution program is：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 32.5 | 0 | 100 |
| 37.5 | 0 | 100 |
| 39 | 100 | 0 |
| 45 | 100 | 0 |
Inventor has found, under above-mentioned elution program (elution is relatively slow), proteic charge variant peak can be with main peak reality
It is now kept completely separate, and peak shape does not generate packet peak phenomenon symmetrically, is convenient for quantitative analysis.
According to an embodiment of the invention, chromatographic column used by the pH-IEC ion-exchange chromatographies is handed over for strong cation
Change chromatographic column SAX, the volume ratio of mobile phase A and Mobile phase B used by the pH-IEC ion-exchange chromatographies is 1:1, and
And used elution program is：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 42.5 | 0 | 100 |
| 47.5 | 0 | 100 |
| 49 | 100 | 0 |
| 55 | 100 | 0 |
Inventor has found that under above-mentioned elution program (elution is slow), proteic charge variant peak can have been realized with main peak
It is fully separating, and peak shape does not generate packet peak phenomenon symmetrically, is convenient for quantitative analysis.
According to an embodiment of the invention, 0.1~1.0mg/ml of sample concentration of pH-IEC ion-exchange chromatographies, applied sample amount
10ul~30ul, 0.5~1.0ml/min of flow velocity, 25~40 DEG C of column temperature, Detection wavelength 280nm.Inventor has found, in above-mentioned color
Under spectral condition, it can be ensured that chromatographic column carrying capacity is moderate, and chromatographic signal intensity is suitable, and peak shape is symmetrical, it can be achieved that making a variation to proteic charge
The accurate quantitative analysis of body, while providing important Quality Control evidence and technical support for process upstream department process exploitation.
According to an embodiment of the invention, it is based on the chromatogram, determines that the content of the testing protein charge alterations body can
It carries out in the following way：Based on proteic charge variant peak area in chromatogram in the ratio of total peak area, albumen electricity is determined
Content of the lotus variant in total protein determines the weight of proteic charge variant in the case of known testing protein total weight
Amount.
In the second aspect of the present invention, a method of detection proteic charge variant, according to an embodiment of the invention, institute
The method of stating includes：Testing protein is analyzed by pH-IEC ion-exchange chromatographies, to obtain chromatogram；And it is based on
The chromatogram determines the content of the testing protein charge alterations body, wherein the pH-IEC ion-exchange chromatographies are adopted
Mobile phase is the mixed solution of piperazine, imidazoles, Tris and water, and the mass ratio of the piperazine, imidazoles and Tris is 2:0.4:
1.2, a concentration of 2g/L of the piperazine, a concentration of 1.2g/L of a concentration of 0.4g/L of the imidazoles, the Tris.It is used
Chromatographic column be strong cation exchange chromatography column SCX, the pH of mobile phase A is 6.5, and the pH of Mobile phase B is 10.5, the pH-IEC
The elution time of ion-exchange chromatography is 30min, and elution slope is 3.3%, the body of used mobile phase A and Mobile phase B
Product is than being 1:1, and used elution program is：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 32.5 | 0 | 100 |
| 37.5 | 0 | 100 |
| 39 | 100 | 0 |
| 45 | 100 | 0 |
Or used chromatographic column is strong anion exchange chromatographic column SAX, the pH of mobile phase A is 10.5, the pH of Mobile phase B
It is 6.5, the elution time of the pH-IEC ion-exchange chromatographies is 40min, and elution slope is 2.5%, used flowing
The volume ratio of phase A and Mobile phase B is 1:1, and used elution program is：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 42.5 | 0 | 100 |
| 47.5 | 0 | 100 |
| 49 | 100 | 0 |
| 55 | 100 | 0 |
0.1~1.0mg/ml of sample concentration, applied sample amount 10ul~30ul, 0.5~1.0ml/min of flow velocity, column temperature 25~40
DEG C, Detection wavelength 280nm.
It can be realized to proteic charge variant using the method for detection proteic charge variant according to the ... of the embodiment of the present invention
It is quick, accurate, delicately detect.Method described herein is particularly suitable for the egg for the recombinant DNA that pI values are 5.5~8.0
The detection of proteic charge variant in white product or recombinant monoclonal antibodies product.
In the third aspect of the present invention, the present invention proposes a kind of method of determining biological products production technology, feature
It is, including：(1) using candidate technique, biological products are prepared, the biological products are protein product；(2) using noted earlier
Method determine the content of charge alterations body in the biological products；And
(3) content based on charge alterations body in the biological products, determines the production technology of final biological products.It utilizes
The method of determining biological products production technology according to the ... of the embodiment of the present invention can carry out stringent prison to the production of biological products
Control ensures safety, validity and the quality controllability of clearance biological products.
According to an embodiment of the invention, the method for above-mentioned determining biological products production technology can further include as follows
At least one additional technical feature：
According to an embodiment of the invention, in step (3), when the content of charge alterations body in the biological products is less than
10% (corresponding charge alterations body peak area is less than 10%), i.e. principal component content are more than 90%, and (corresponding main peak area is more than
90%), then select the candidate technique for the production technology of final biological products.Charge alterations body contains in the biological products
Amount is less than 10%, then the main peak area in the biological products is more than 90%, and the activity of gained protein biology product is unaffected
Or influence to be in level of security, producing the candidate technique of the biological products can select.
According to an embodiment of the invention, when the content of charge alterations body in the biological products be not less than 10%, then to institute
It states candidate technique and optimizes processing, and repeat step (1)~(3) until the content of charge alterations body is small in the biological products
In 10%.The biological products variant peak area be not less than 10%, the activity of gained biological products be affected or influence at
In dangerous level, then the candidate technique for producing the biological products is needed to adjust and be improved, until the biological products produced
Charge alterations body is in level of security, can just let pass.
According to an embodiment of the invention, the optimization processing includes being adjusted to the parameter of at least one lower column processing：
Zymotechnique, purifying process, preparation prescription and condition of storage.According to a particular embodiment of the invention, preparation prescription include salt from
The process conditions such as subcategory, ionic strength, pH value, the stoste fermented as used by condition of storage after purification freeze in -80 DEG C,
Finished product is placed in 2~8 DEG C and is protected from light.Inventor has found that zymotechnique, purifying process, preparation prescription and condition of storage are to influence albumen
The key parameter of drug charge variant modification can make the charge alterations body of the protein drug of output by adjusting above-mentioned parameter
In level of security.
Description of the drawings
Fig. 1 is the PIT systems mobile phase composition (mass ratio 1 according to the embodiment of the present invention:0.2:0.6) pH-HPLC chromatographies
Figure；
Fig. 2 is the PIT systems mobile phase composition (mass ratio 1 according to the embodiment of the present invention:0.1:0.3) pH-HPLC chromatographies
Figure；
Fig. 3 is the PIT systems mobile phase composition (mass ratio 2 according to the embodiment of the present invention:0.4:1.2) pH-HPLC chromatographies
Figure；
Fig. 4 is PIT systems mobile phase (A phase 5.5B phases 8.5) pH-HPLC chromatograms according to the embodiment of the present invention；
Fig. 5 is PIT systems mobile phase (A phase 6.5B phases 10.5) pH-HPLC chromatograms according to the embodiment of the present invention；
Fig. 6 is PIT system mobile phase (elution time 15min) pH-HPLC chromatograms according to the embodiment of the present invention；
Fig. 7 is PIT system mobile phase (elution time 20min) pH-HPLC chromatograms according to the embodiment of the present invention；
Fig. 8 is PIT system mobile phase (elution time 30min) pH-HPLC chromatograms according to the embodiment of the present invention；
Fig. 9 is PIT systems mobile phase (Propac WCX-10 chromatographic columns) pH-HPLC chromatographies according to the embodiment of the present invention
Figure；And
Figure 10 is PIT systems mobile phase (Propac SAX-10 chromatographic columns) pH-HPLC chromatographies according to the embodiment of the present invention
Figure.
Specific implementation mode
The embodiment of the present invention is described below in detail.The embodiments described below is exemplary, and is only used for explaining this hair
It is bright, and be not considered as limiting the invention.Particular technique or condition are not specified in embodiment, according to text in the art
It offers described technology or condition or is carried out according to product description.Reagents or instruments used without specified manufacturer,
For can be with conventional products that are commercially available.
Experiment material used, sample to be tested and instrument are as described below in following embodiment：
Main agents information is as shown in table 1.
Table 1：
| Title | Article No. | Specification | Manufacturer |
| Piperazine (P) | P45907 | 100g | Sigma |
| Imidazoles (I) | I1202 | 100g | Sigma |
| Tris(T) | T6066 | 100g | Sigma |
Sample and device information are as shown in table 2 and table 3.
Table 2：
| Title | Specification | Producer |
| Monoclonal antibody B | 1mg/ml | Self-control |
Table 3：
Embodiment 1
Inventor carried out early period a large number of experiments method grope (including flowing phase composition, flowing phase pH value, elution time and
Chromatographic column is screened), test method key parameter is finally determined, and be successfully applied to the detection and analysis of proteic charge variant,
Determination for technique department key process parameter (CPPs) provides theoretical foundation and reference, it is ensured that the safety of clinical application
And validity.
1.1 mobile phase compositions are groped
Condition 1：
It is as shown in table 4 that PIT flows phase composition.
Table 4：
Chromatographic condition is as shown in table 5.
Table 5：
| Conditional content | Title/index |
| Liquid chromatograph | Agilent 1260 or Waters e2695 |
| Detector/Detection wavelength | 280nm |
| Chromatographic column | Proteomix SCX-NP5 (4.6*250mm, 5 μm, Sepax) |
| Flow velocity | 1.0ml/min |
| Sample concentration | 1.0mg/ml |
| Sample size | 20μl |
| Acquisition time | 35min |
| Column temperature | 30℃ |
Elution program is as shown in table 6, elution time 20min.
Table 6：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 22.5 | 0 | 100 |
| 27.5 | 0 | 100 |
| 29 | 100 | 0 |
| 35 | 100 | 0 |
Gained chromatogram is as shown in Figure 1.The results show that PIT system mobile phase composition mass ratioes are 1:0.2:0.6 chromatogram
The acid peak of display is not kept completely separate with main peak, need to adjust mobile phase composition proportioning, variant peak is made to be kept completely separate.
Condition 2：
It is as shown in table 7 that PIT flows phase composition.
Table 7：
Chromatographic condition is as shown in table 8.
Table 8：
| Conditional content | Title/index |
| Liquid chromatograph | Agilent 1260 or Waters e2695 |
| Detector/Detection wavelength | 280nm |
| Chromatographic column | Proteomix SCX-NP5 (4.6*250mm, 5 μm, Sepax) |
| Flow velocity | 1.0ml/min |
| Sample concentration | 1.0mg/ml |
| Sample size | 20μl |
| Acquisition time | 35min |
| Column temperature | 30℃ |
Elution program is as shown in table 9, elution time 20min.
Table 9：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 22.5 | 0 | 100 |
| 27.5 | 0 | 100 |
| 29 | 100 | 0 |
| 35 | 100 | 0 |
Gained chromatogram is as shown in Figure 2.The results show that by adjusting PIT system mobile phase compositions, acidic variant peak with
Main peak is overlapped, unfavorable to sample Analysis of quality control, still needs to adjustment relevant parameter to obtain desired result.
Condition 3：
It is as shown in table 10 that PIT flows phase composition.
Table 10：
Chromatographic condition is as shown in table 11.
Table 11：
| Conditional content | Title/index |
| Liquid chromatograph | Agilent 1260 or Waters e2695 |
| Detector/Detection wavelength | 280nm |
| Chromatographic column | Proteomix SCX-NP5 (4.6*250mm, 5 μm, Sepax) |
| Flow velocity | 1.0ml/min |
| Sample concentration | 1.0mg/ml |
| Sample size | 20μl |
| Acquisition time | 35min |
| Column temperature | 30℃ |
Elution program is as shown in table 12, elution time 20min.
Table 12：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 22.5 | 0 | 100 |
| 27.5 | 0 | 100 |
| 29 | 100 | 0 |
| 35 | 100 | 0 |
Gained chromatogram is as shown in Figure 3.The results show that by adjusting PIT system mobile phase compositions, each variant peak is basic
It is detached with main peak realization, obtains ideal test result.
2.2 flowing phase pH values are groped
Condition 1：
It is as shown in table 13 that PIT flows phase composition.
Table 13：
Chromatographic condition is as shown in table 14.
Table 14：
| Conditional content | Title/index |
| Liquid chromatograph | Agilent 1260 or Waters e2695 |
| Detector/Detection wavelength | 280nm |
| Chromatographic column | Proteomix SCX-NP5 (4.6*250mm, 5 μm, Sepax) |
| Flow velocity | 1.0ml/min |
| Sample concentration | 1.0mg/ml |
| Sample size | 20μl |
| Acquisition time | 35min |
| Column temperature | 30℃ |
Elution program is as shown in Table 15, elution time 20min.
Table 15：
| Time | %A | %B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 22.5 | 0 | 100 |
| 27.5 | 0 | 100 |
| 29 | 100 | 0 |
| 35 | 100 | 0 |
Gained chromatogram is as shown in Figure 4.The results show that PIT flow visualizings are under the conditions of A phases 5.5, B phases 8.5, it is each to become
Allosome peak separating degree substantially conforms to require, but appearance time is too late, and showing under this method pH gradient, smaller (i.e. B phases pH value is inclined
It is low), it is unfavorable for the separation at variant peak, should subsequently increases pH gradient, appearance time is made suitably to shift to an earlier date.
Condition 2：
It is as shown in table 16 that PIT flows phase composition.
Table 16：
Chromatographic condition is as shown in table 17.
Table 17：
Elution program is as shown in table 18, elution time 20min.
Table 18：
| Time | %A | %B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 22.5 | 0 | 100 |
| 27.5 | 0 | 100 |
| 29 | 100 | 0 |
| 35 | 100 | 0 |
Gained chromatogram is as shown in Figure 5.The results show that by adjusting A, B phase pH value, pH gradient is made suitably to increase, retained
Time is suitable, meets expection, but separation is not implemented in acidic variant peak, Chong Die with main peak, need to subsequently be washed in conjunction with adjustment mobile phase
De- time (changing elution slope), improves eluting peak resolving power, realizes being kept completely separate for each variant peak.
1.3 mobile phase elution times are groped
Condition 1：
It is as shown in table 19 that PIT flows phase composition.
Table 19：
Chromatographic condition is as shown in table 20.
Table 20：
Elution program is as shown in table 21, elution time 15min.
Table 21：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 17.5 | 0 | 100 |
| 22.5 | 0 | 100 |
| 24 | 100 | 0 |
| 30 | 100 | 0 |
Gained chromatogram is as shown in Figure 6.The results show that elution time is 15min (it is 6.7% to elute slope), target
Proteic charge variant can not be kept completely separate, and resolving power is poor (packet peak phenomenon), need to suitably reduce elution slope, realize each peak
Good separation.
Condition 2：
It is as shown in table 22 that PIT flows phase composition.
Table 22：
Chromatographic condition is as shown in table 23.
Table 23：
Elution program is as shown in table 24, elution time 20min.
Table 24：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 22.5 | 0 | 100 |
| 27.5 | 0 | 100 |
| 29 | 100 | 0 |
| 35 | 100 | 0 |
Gained chromatogram is as shown in Figure 7.The results show that elution time is 20min (it is 5.0% to elute slope), target
Can not still being detached with main peak for proteic charge variant, need to further decrease elution slope, realize the good separation of variant.
Condition 3：
It is as shown in Table 25 that PIT flows phase composition.
Table 25：
Chromatographic condition is as shown in table 26.
Table 26：
| Conditional content | Title/index |
| Liquid chromatograph | Agilent 1260 or Waters e2695 |
| Detector/Detection wavelength | 280nm |
| Chromatographic column | Proteomix SCX-NP5 (4.6*250mm, 5 μm, Sepax) |
| Flow velocity | 1.0ml/min |
| Sample concentration | 1.0mg/ml |
| Sample size | 20μl |
| Acquisition time | 45min |
| Column temperature | 30℃ |
Elution program is as shown in table 27, elution time 30min.
Table 27：
Gained chromatogram is as shown in Figure 8.The results show that elution time is 30min (it is 3.3% to elute slope), target
The separating degree ＞ 1.5 at proteic charge variant peak and main peak meets acceptable standard, therefore with this condition can be to target protein
Acidic variant and alkaline variant realization are kept completely separate.
The screening of 3.4 chromatographic columns
Inventor is in early period using strong cation exchange chromatography column SCX (Strong Cation Exchange) to target egg
The white separation for having carried out charge alterations body, obtains ideal separating effect.It is follow-up to use weakly strictly diagonally dominant matrix column WCX again
(Weak Cation Exchange) analyzes charge heterogeneity, does not reach desired effect.
Inventor is handed on the basis of to aforementioned invention achievement and ion-exchange chromatography principle profound understanding using strong anion
Change chromatographic column SAX and (pH value of mobile phase A and B phases is opposite) analyzed to target protein charge alterations body again, as a result with
SCX results are consistent, further demonstrate the applicability of the method.
Condition 1 (chromatographic column WCX)：
It is as shown in table 28 that PIT flows phase composition.
Table 28：
Chromatographic condition is as shown in table 29.
Table 29：
Elution program is as shown in table 30, elution time 40min.
Table 30：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 42.5 | 0 | 100 |
| 47.5 | 0 | 100 |
| 50 | 100 | 0 |
| 55 | 100 | 0 |
Gained chromatogram is as shown in Figure 9.The results show that carrying out charge alterations body using weakly strictly diagonally dominant matrix column WCX
Separation, appearance time is too early, and variant peak not with main peak realize good separation, influence Analysis of quality control, therefore should not use
WCX analyzes proteic charge variant.
Condition 2 (chromatographic column SAX)：
It is as shown in table 31 that PIT flows phase composition.
Table 31：
Chromatographic condition is as shown in table 32.
Table 32：
| Conditional content | Title/index |
| Liquid chromatograph | Agilent 1260 or Waters e2695 |
| Detector/Detection wavelength | 280nm |
| Chromatographic column | Propac SAX-10 (4*250mm, 10 μm, Thermo) |
| Flow velocity | 1.0ml/min |
| Sample concentration | 1.0mg/ml |
| Sample size | 20μl |
| Acquisition time | 60min |
| Column temperature | 30℃ |
Elution program is as shown in table 33, elution time 40min.
Table 33：
| Time | A | B |
| 0 | 100 | 0 |
| 2.5 | 100 | 0 |
| 42.5 | 0 | 100 |
| 47.5 | 0 | 100 |
| 49 | 100 | 0 |
| 55 | 100 | 0 |
Gained chromatogram is as shown in Figure 10.The results show that inventor carries out albumen using strong anion exchange chromatographic column SAX
The analysis of variant, same achievable charge alterations body are kept completely separate, and show that pH-IEC methods detach charge alterations body applicability
It is good, it is versatile.
Inventor compares and analyzes proteic charge variant using 1 different condition of embodiment, studies different chromatostrips
The separating effect of charge alterations body under part is detected with filtering out optimal method for proteic charge variant, further to electricity
Lotus variant has carried out digestion discriminating, determines the classification of charge alterations body, instructs process upstream department, and then determine critical process
Parameter (CPPs), it is ensured that drug production batch between consistency, monitor safety and the validity of clinical application.
To sum up, pH-IEC methods described herein are suitable for weight (no matter using SCX chromatographic columns or using SAX chromatographic columns)
Histone or the analysis of the charge alterations body of monoclonal antibody, can be used for the field of quality control of such drug.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or spy described in conjunction with this embodiment or example
Point is included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms are not
It must be directed to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be in office
It can be combined in any suitable manner in one or more embodiments or example.In addition, without conflicting with each other, the skill of this field
Art personnel can tie the feature of different embodiments or examples described in this specification and different embodiments or examples
It closes and combines.
Although the embodiments of the present invention has been shown and described above, it is to be understood that above-described embodiment is example
Property, it is not considered as limiting the invention, those skilled in the art within the scope of the invention can be to above-mentioned
Embodiment is changed, changes, replacing and modification.
Claims (10)
1. a kind of method of detection proteic charge variant, which is characterized in that by pH-IEC ion-exchange chromatographies to be measured
Albumen is analyzed, to obtain chromatogram；And
Based on the chromatogram, the content of the testing protein charge alterations body is determined.
2. according to the method described in claim 1, it is characterized in that, flowing used by the pH-IEC ion-exchange chromatographies
It is mutually the mixed solution of piperazine, imidazoles, Tris and water, wherein the mass ratio of the piperazine, imidazoles and Tris is 2:0.4:1.2.
3. according to the method described in claim 2, it is characterized in that, a concentration of 2g/L of the piperazine, the concentration of the imidazoles
For 0.4g/L, a concentration of 1.2g/L of the Tris.
4. according to the method described in claim 1, it is characterized in that, chromatography used by the pH-IEC ion-exchange chromatographies
Column is strong cation exchange chromatography column SCX or strong anion exchange chromatographic column SAX.
5. according to the method described in claim 1, it is characterized in that, chromatography used by the pH-IEC ion-exchange chromatographies
Column is strong cation exchange chromatography column SCX, and the pH of mobile phase A is 6.5, and the pH of Mobile phase B is 10.5.
6. according to the method described in claim 1, it is characterized in that, chromatography used by the pH-IEC ion-exchange chromatographies
Column is strong anion exchange chromatographic column SAX, and the pH of mobile phase A is 10.5, and the pH of Mobile phase B is 6.5.
7. according to the method described in claim 1, it is characterized in that, chromatography used by the pH-IEC ion-exchange chromatographies
Column is strong cation exchange chromatography column SCX, and the elution time of the pH-IEC ion-exchange chromatographies is 30min, elutes slope
It is 3.3%,
Optionally, chromatographic column used by the pH-IEC ion-exchange chromatographies is strong anion exchange chromatographic column SAX, described
The elution time of pH-IEC ion-exchange chromatographies is 40min, and elution slope is 2.5%.
8. according to the method described in claim 1, it is characterized in that, chromatography used by the pH-IEC ion-exchange chromatographies
Column is strong cation exchange chromatography column SCX, mobile phase A and Mobile phase B used by the pH-IEC ion-exchange chromatographies
Volume ratio is 1:1, and used elution program is：
Optionally, chromatographic column used by the pH-IEC ion-exchange chromatographies is strong anion exchange chromatographic column SAX, described
The volume ratio of mobile phase A and Mobile phase B used by pH-IEC ion-exchange chromatographies is 1:1, and used elution journey
Sequence is：
Optionally, 0.1~1.0mg/ml of sample concentration of the pH-IEC ion-exchange chromatographies, applied sample amount 10ul~30ul,
0.5~1.0ml/min of flow velocity, 25~40 DEG C of column temperature, Detection wavelength 280nm.
9. a kind of method of detection proteic charge variant, which is characterized in that by pH-IEC ion-exchange chromatographies to be measured
Albumen is analyzed, to obtain chromatogram；And
Based on the chromatogram, the content of the testing protein charge alterations body is determined,
Wherein, mobile phase used by the pH-IEC ion-exchange chromatographies is that the mixing of piperazine, imidazoles, Tris and water is molten
The mass ratio of liquid, the piperazine, imidazoles and Tris is 2:0.4:1.2, a concentration of 2g/L of the piperazine, the concentration of the imidazoles
For 0.4g/L, a concentration of 1.2g/L of the Tris,
Used chromatographic column is strong cation exchange chromatography column SCX, and the pH of mobile phase A is 6.5, and the pH of Mobile phase B is 10.5,
The elution time of the pH-IEC ion-exchange chromatographies is 30min, and elution slope is 3.3%, used mobile phase A and stream
The volume ratio of dynamic phase B is 1:1, and used elution program is：
Or
Used chromatographic column is strong anion exchange chromatographic column SAX, and the pH of mobile phase A is 10.5, and the pH of Mobile phase B is 6.5,
The elution time of the pH-IEC ion-exchange chromatographies is 40min, and elution slope is 2.5%, used mobile phase A and stream
The volume ratio of dynamic phase B is 1:1, and used elution program is：
0.1~1.0mg/ml of sample concentration, applied sample amount 10ul~30ul, 0.5~1.0ml/min of flow velocity, 25~40 DEG C of column temperature, inspection
Survey wavelength 280nm.
10. a kind of method of determining biological products production technology, which is characterized in that including：
(1) using candidate technique, biological products are prepared, the biological products are protein product；
(2) content of charge alterations body in the biological products is determined using claim 1~9 any one of them method；With
And
(3) content based on charge alterations body in the biological products, determines the production technology of final biological products,
Optionally, in step (3), when charge alterations body in the biological products content be less than 10%, then select the time
It is the production technology of final biological products to select technique,
Optionally, when the content of charge alterations body in the biological products is not less than 10%, then the candidate technique is carried out excellent
Change handle, and repeat step (1)~(3) until the biological products in charge alterations body content be less than 10%,
Optionally, the optimization processing includes being adjusted to the parameter of at least one lower column processing：
Zymotechnique, purifying process, preparation prescription and condition of storage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710042581.9A CN108333261A (en) | 2017-01-20 | 2017-01-20 | The method for detecting the method for proteic charge variant and determining biological products production technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710042581.9A CN108333261A (en) | 2017-01-20 | 2017-01-20 | The method for detecting the method for proteic charge variant and determining biological products production technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108333261A true CN108333261A (en) | 2018-07-27 |
Family
ID=62921994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710042581.9A Pending CN108333261A (en) | 2017-01-20 | 2017-01-20 | The method for detecting the method for proteic charge variant and determining biological products production technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108333261A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111024883A (en) * | 2019-12-31 | 2020-04-17 | 上海博威生物医药有限公司 | Separation method of charge heteroplasmon of omalizumab |
| CN114544839A (en) * | 2022-01-20 | 2022-05-27 | 未名生物医药有限公司 | Charge variant detection method for anti-human nerve growth factor antibody |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103217489A (en) * | 2013-01-15 | 2013-07-24 | 珠海市丽珠单抗生物技术有限公司 | Method for determining sample glycosylation and terminal modification states during protein purification process |
| CN103217499A (en) * | 2013-01-15 | 2013-07-24 | 珠海市丽珠单抗生物技术有限公司 | Method for determining immunoglobulin charge isomer glycosylation and terminal modification states |
| EP3068417A1 (en) * | 2013-11-15 | 2016-09-21 | F. Hoffmann-La Roche AG | Methods for viral inactivation using eco-friendly detergents |
-
2017
- 2017-01-20 CN CN201710042581.9A patent/CN108333261A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103217489A (en) * | 2013-01-15 | 2013-07-24 | 珠海市丽珠单抗生物技术有限公司 | Method for determining sample glycosylation and terminal modification states during protein purification process |
| CN103217499A (en) * | 2013-01-15 | 2013-07-24 | 珠海市丽珠单抗生物技术有限公司 | Method for determining immunoglobulin charge isomer glycosylation and terminal modification states |
| EP3068417A1 (en) * | 2013-11-15 | 2016-09-21 | F. Hoffmann-La Roche AG | Methods for viral inactivation using eco-friendly detergents |
Non-Patent Citations (3)
| Title |
|---|
| DELL FARNAN.ET AL.: "Multiproduct High-Resolution Monoclonal Antibody Charge Variant Separations by pH Gradient Ion-Exchange Chromatography", 《ANAL CHEM》 * |
| 戴振宇 等: "pH梯度离子交换色谱高分辨率分离单抗唾液酸化异构体", 《HTTPS://WWW.DOCIN.COM/P-870882521.HTML》 * |
| 程洪杰 等: "单克隆抗体电荷异构体分离方法优化", 《中国医药生物技术》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111024883A (en) * | 2019-12-31 | 2020-04-17 | 上海博威生物医药有限公司 | Separation method of charge heteroplasmon of omalizumab |
| CN111024883B (en) * | 2019-12-31 | 2022-12-06 | 上海博威生物医药有限公司 | Separation method of charge heteroplasmon of omalizumab |
| CN114544839A (en) * | 2022-01-20 | 2022-05-27 | 未名生物医药有限公司 | Charge variant detection method for anti-human nerve growth factor antibody |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hage et al. | Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments | |
| Fabri et al. | Structural characterisation of native and recombinant forms of the neurotrophic cytokine MK | |
| Chen et al. | Comprehensive two-dimensional HepG2/cell membrane chromatography/monolithic column/time-of-flight mass spectrometry system for screening anti-tumor components from herbal medicines | |
| Lönnberg et al. | Rapid affinity purification of erythropoietin from biological samples using disposable monoliths | |
| CN108333264A (en) | The method for detecting the method for proteic charge variant and determining biological products production technology | |
| Fekete et al. | High resolution reversed phase analysis of recombinant monoclonal antibodies by ultra-high pressure liquid chromatography column coupling | |
| CN103217489A (en) | Method for determining sample glycosylation and terminal modification states during protein purification process | |
| CN108333261A (en) | The method for detecting the method for proteic charge variant and determining biological products production technology | |
| Kovács et al. | Medicinal chemistry meets proteomics: fractionation of the human plasma proteome | |
| CN107849122A (en) | Affinitive layer purification is carried out with low conductivity lavation buffer solution | |
| CN105241973B (en) | The high-efficiency liquid chromatography method for detecting of protein formulation | |
| Marek et al. | Isolation of monoclonal antibody from a Chinese hamster ovary supernatant. I: Assessment of different separation concepts | |
| Breen et al. | High-throughput fractionation of human plasma for fast enrichment of low-and high-abundance proteins | |
| CN115541777B (en) | Method for evaluating exosome purity based on two-dimensional liquid phase | |
| Mallorqui et al. | New screening protocol for recombinant human erythropoietins based on differential elution after immunoaffinity purification | |
| Forrer et al. | Chromatographic behavior of a polyclonal antibody mixture on a strong cation exchanger column. Part I: Adsorption characterization | |
| Wiehle et al. | Isoforms of estrogen receptors by high-performance ion-exchange chromatography | |
| CN111239278B (en) | Method for detecting recombinant human interleukin-12 protein charge variant and application | |
| CN212375283U (en) | System for on-line monitoring yield and quality of target protein | |
| CN106290600B (en) | A method of with liquid chromatography, separation health Buddhist nun replaces Buddhist nun and related substance | |
| Zhan et al. | Characterization of interactions between taspine derivate TPD7 and EGF receptor by cell membrane chromatography with zonal elution and frontal analysis | |
| Kamineni et al. | Musculoskeletal protein analysis techniques—a review | |
| Li et al. | Simultaneous Determination of Six Alkaloids in Rat Plasma with On-line SPE–HPLC Using a Homemade Four-Hydrogen Furfuryl-Based Polymer Monolithic Sorbent | |
| CN108918749A (en) | A kind of reversed-phase HPLC detection method of nevin fibrinolytic enzyme | |
| Arnaud et al. | Interaction of α2-hs-glycoprotein with immobilized triazine dyes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180727 |